Status:
COMPLETED
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatit...
Eligibility Criteria
Inclusion
- Documented clinical history compatible with chronic hepatitis C and compensated liver disease
- Failed response to previous hepatitis C therapy of pegylated interferon/ribavirin
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant or breastfeeding
- Patient is co-infected with hepatitis B or HIV
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00120861
Start Date
January 1 2005
Last Update
June 10 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Los Angeles, California, United States
3
San Francisco, California, United States
4
Miami, Florida, United States